title: [Current trends in classification and treatment of systemic vasculitis associated with anti-neutrophilic cytoplasmic antibodies: results of 2011].
abstract: Systemic vasculitis (SV) pathogenetically associated with anti-neutrophilic cytoplasmic antibodies (ANCA) is the subject of intensive research in present-day rheumatology. There were noticeable changes in ANCA-associated SV (ANCA-SV) nomenclature in 2011 as well as mid-term success was achieved in the study of biological anti-B-cell therapy in this disease. European recommendations on rituximab administration in ANCA-SV have been developed Russian Register of ANCA-SV patients on rituximab treatment is presented. State-of the art in ANCA-SV research is reviewed.
authors: T V
authors: TV
authors: Beketovа
authors: E L
authors: EL
authors: Nasonov
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000145:classification / Q000276:immunology / Q000628:therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D012042:Registries; D000069283:Rituximab; D012426:Russia; D014657:Vasculitis
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab